The goal of this clinical study is to learn more about the safety and effectiveness of the study drugs, KITE-363 and KITE-753, in participants with relapsed an…

Relapsed and/or Refractory B-cell Lymphoma

~Estimated

~$10 – $7,500

Kite, A Gilead CompanyNCT04989803

Observational Study of Commercial Chimeric Antigen Receptor T-cell (CAR T) Therapy in Older Patients With Hematologic Malignancies and With an Embedded Pilot Study of Longitudinal Geriatric and Neurocognitive Evaluation

This study is being done to find out how older patients respond to CAR-T cell therapy and how the treatment affects their quality of life. This is a quality of…

LymphomaRefractory B-Cell LymphomaLymphoma, B-Cell+3 more

~Estimated

~$10 – $750

Memorial Sloan Kettering Cancer CenterNCT04300998